This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| ShAT | |
|---|---|
| Name | ShAT |
ShAT is a biochemical factor characterized as a small acetyltransferase-like entity implicated in cellular acetylation processes across diverse taxa. First identified in targeted screens of acetylome modifiers, ShAT has been associated with modulation of protein function, signaling cascades, and metabolic regulation. Its study intersects proteomics, structural biology, and medical genetics, attracting interest from groups working on post-translational modification, enzyme mechanism, and disease biomarkers.
The name ShAT was coined in a comparative proteomics paper contrasting acetyltransferase homologues from model organisms such as Saccharomyces cerevisiae, Drosophila melanogaster, and Mus musculus. Nomenclatural discussions occurred at meetings convened by consortia including the Human Proteome Organization and the European Molecular Biology Laboratory. Early database entries in resources maintained by the National Center for Biotechnology Information and the Universal Protein Resource adopted the abbreviation to reflect structural similarity to canonical acetyltransferases studied at institutions such as the Max Planck Institute and the Cold Spring Harbor Laboratory.
Structural characterization of ShAT has relied on methods developed at facilities such as the European Synchrotron Radiation Facility, the Stanford Synchrotron Radiation Lightsource, and the Diamond Light Source. Crystallographic models revealed a fold reminiscent of the GNAT family studied in work on Escherichia coli acetyltransferases and enzymes from Homo sapiens. High-resolution structures determined by groups at the Scripps Research Institute demonstrated an active-site pocket accommodating acetyl-CoA analogues used in assays pioneered by researchers at the Karolinska Institutet and the University of Cambridge.
Mechanistic insights were informed by kinetic analyses influenced by classical studies from the Max Planck Institute for Biophysical Chemistry and inhibitor development programs at the Novartis Institutes for BioMedical Research. Catalysis appears to proceed via nucleophilic attack on the acetyl donor with transition-state stabilization comparable to reactions described for enzymes in the GNAT superfamily analyzed by teams at the Massachusetts Institute of Technology and the University of California, San Francisco.
Functional studies in model systems including Caenorhabditis elegans, Danio rerio, and Arabidopsis thaliana implicated ShAT in regulation of protein stability, subcellular trafficking, and signaling pathways. Proteomic mapping by laboratories at the Broad Institute and the Whitehead Institute identified candidate substrates among proteins previously characterized in signaling networks by investigators at the University of Oxford and the Johns Hopkins University. Cellular phenotypes recapitulated in lines developed at the University of California, Berkeley suggested roles in stress responses characterized in research from the National Institutes of Health and the Howard Hughes Medical Institute.
ShAT activity has been linked to modulation of proteins studied in pathways involving molecules researched at the Max Delbrück Center and the Yale University School of Medicine, and to post-translational networks cataloged by the ProteomeXchange Consortium and the European Bioinformatics Institute.
Altered ShAT expression or function has been reported in clinical cohorts assembled at centers such as the Mayo Clinic, the Cleveland Clinic, and the Memorial Sloan Kettering Cancer Center. Correlative studies published from consortia including the Cancer Genome Atlas and the International Cancer Genome Consortium associated ShAT variants with prognostic signatures in malignancies investigated at the Dana-Farber Cancer Institute and the Fred Hutchinson Cancer Center. Clinical researchers at the John Radcliffe Hospital and the Royal Marsden Hospital explored ShAT as a biomarker for treatment response in trials coordinated with pharmaceutical partners like AstraZeneca and Roche.
Therapeutic interest has driven small-molecule screening efforts at biotechnology groups modeled after platforms at Genentech and Gilead Sciences, with translational collaborations involving the Wellcome Trust and national health agencies such as the Medical Research Council.
Genetic analyses leveraging datasets from the 1000 Genomes Project, the UK Biobank, and the Exome Aggregation Consortium uncovered polymorphisms in loci encoding ShAT-like sequences. Molecular cloning and expression systems established by teams at the University of Tokyo and the Weizmann Institute of Science facilitated mutational scans akin to those performed at the Broad Institute and the Sanger Institute. Functional genomics approaches integrating CRISPR methods popularized by the Zhang Lab and screens from the Addgene community library probed loss- and gain-of-function effects.
Transcriptomic profiling in cohorts studied by the Genotype-Tissue Expression Project and disease registries curated by the Centers for Disease Control and Prevention provided tissue-specific expression maps often cited alongside work from the Karolinska Institutet.
Assay development for ShAT activity adopted technologies adapted from proteomics workflows at the European Molecular Biology Laboratory and mass spectrometry platforms from the Thermo Fisher Scientific collaborations. Enzyme-linked assays and fluorescence-based reporter systems built on methodologies from the National Institute of Standards and Technology and the Roche Diagnostics pipeline enabled high-throughput screening. Antibodies raised and validated in labs affiliated with the Antibody Society and reagents distributed through repositories like the American Type Culture Collection supported immunodetection in studies at the Mount Sinai Hospital and the Princeton University.
Comparative genomics surveys performed by consortia including the Ensembl project and the Comparative Genomics Centre detected conserved motifs in ShAT homologues across clades represented by Saccharomyces cerevisiae, Schizosaccharomyces pombe, Caenorhabditis elegans, Drosophila melanogaster, Danio rerio, Xenopus laevis, Mus musculus, and Homo sapiens. Phylogenetic analyses drawing on datasets curated by the Tree of Life Web Project and the National Center for Biotechnology Information highlighted a conserved catalytic architecture paralleling acetyltransferases characterized in classical studies from the University of Göttingen and the Institut Pasteur.
Category:Proteins